Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Clinical activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU11248 in patients with malignant gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate

Demetri GD, Heinrich MC, Fletcher JA, Fletcher CDM, George S, Desai J, Cohen DP, Scigalla P, Cherrington JM, Van den Abbeele AD. Clinical activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU11248 in patients with malignant gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate. Proc Am Soc Clin Oncol. 2003; 22:814A.


© 2021 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.